drugset / Trial / NCT00275262
A Study to Evaluate the Ability of Lupron Depot to Enhance Immune Function Following Bone Marrow Transplantation
Phase 2
Terminated
25 enrolled
Abbott
Dana-Farber Cancer Institute · collabM.D. Anderson Cancer Center · collabNorwood Immunology Limited · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
Phase 2 study, conducted in patients with Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, or mantle cell lymphoma undergoing high-dose chemotherapy and autologous stem cell transplantation.
Timeline
- Start
- 2006-02
- Primary completion
- 2009-02
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Leuprolide | Other / unclassified | 11.25 mg | Intramuscular |
| Background | key limpet hemocyanin | Vaccine | 1 mg | Subcutaneous |